Cookies?
Library Header Image
LSE Research Online LSE Library Services

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective

von Dach, E., Morel, C. M., Murthy, A., Pagani, L., Macedo-Vinas, M., Olearo, F. and Harbarth, S. (2017) Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective. Clinical Microbiology and Infection, 23 (9). pp. 659-666. ISSN 1198-743X

[img]
Preview
PDF - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (12MB) | Preview
Identification Number: 10.1016/j.cmi.2017.02.011

Abstract

To date few industry-independent studies were conducted to compare the relative costs and benefits of drugs to treat MRSA infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies -- linezolid versus trimethoprim-sulfamethoxazole plus rifampicin -- for the treatment of MRSA infection.

Item Type: Article
Official URL: http://www.clinicalmicrobiologyandinfection.com/
Additional Information: © 2017 The Authors © CC BY-NC-ND 4.0
Divisions: Social Policy
LSE Health
Subjects: R Medicine > R Medicine (General)
R Medicine > RA Public aspects of medicine
Sets: Departments > Social Policy
Research centres and groups > LSE Health
Date Deposited: 01 Mar 2017 18:15
Last Modified: 30 Jan 2019 20:44
URI: http://eprints.lse.ac.uk/id/eprint/69613

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics